# Massive Submacular Hemorrhage Following Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration

## TL;DR

A patient developed severe eye bleeding after a faricimab injection for macular degeneration, causing permanent vision damage.

## Contribution

Reports a new severe hemorrhagic complication of faricimab not previously documented in clinical trials.

## Key findings

- Massive submacular hemorrhage occurred three days after faricimab injection.
- This adverse event was not listed in clinical trial safety data for faricimab.
- The complication caused irreversible visual damage despite close patient monitoring.

## Abstract

We report a case of massive submacular hemorrhage (SMH) in a patient with neovascular age-related macular degeneration (AMD) occurring three days after intravitreal faricimab injection. While faricimab has demonstrated a favorable safety profile and lower hemorrhagic events compared to other anti-vascular endothelial growth factor agents, SMH, in specific, is not listed among the significant adverse events in available clinical trial safety data or in postmarketing pharmacovigilance analyses. This case highlights a new severe hemorrhagic complication that can cause permanent visual damage related to faricimab even in well-monitored patients.